lenalidomide analog KPG-121

A lenalidomide analog with potential anti-angiogenic and immunomodulatory activities. Upon oral administration, lenalidomide analog KPG-121 may inhibit tumor necrosis factor alpha (TNF-alpha) production, stimulate T-lymphocytes, reduce serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF; FGF2), and inhibit angiogenesis. Additionally, KPG-121 may promote G1 cell cycle arrest and induce apoptosis in malignant cells.